https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Intensive therapy after botulinum toxin in adults with spasticity after stroke versus botulinum toxin alone or therapy alone: a pilot, feasibility randomized trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32873 Wed 19 Jan 2022 15:17:04 AEDT ]]> Stroke survivors’ perceptions of the factors that influence engagement in activity outside dedicated therapy sessions in a rehabilitation unit: A qualitative study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51671 Wed 13 Sep 2023 10:07:41 AEST ]]> Effect of additional rehabilitation after totulinum toxin-A on upper limb activity in chronic stroke The InTENSE Trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45683 3 months ago, who had completed formal rehabilitation and had no significant cognitive impairment. Experimental group received botulinum toxin-A plus evidence-based movement training while the control group received botulinum toxin-A plus a handout of exercises. Primary outcomes were goal attainment (Goal Attainment Scaling) and upper limb activity (Box and Block Test) at 3 months (end of intervention). Secondary outcomes were spasticity, range of motion, strength, pain, burden of care, and health-related quality of life. Results: In terms of goal attainment, the experimental group scored the same (mean difference, 2 T-score [95% CI, −2 to 7]) as the control group on the Goal Attainment Scale. In terms of upper limb activity, by 3 months the experimental group moved blocks at the same speed (mean difference, 0.00 blocks/s [95% CI, −0.02 to 0.01]) as the control group on the Box and Block Test. There were no differences between groups on any secondary outcome except strength, in favor of the experimental group (mean difference, 1.4 kg [95% CI, 0.2–2.7]). Conclusions: Findings suggest that additional intensive upper limb rehabilitation following botulinum toxin-A in chronic stroke survivors with a disabled upper limb is not effective. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: ACTRN12615000616572. (Stroke. 2020;51:556-562. DOI: 10.1161/STROKEAHA.119.027602.)]]> Tue 21 Mar 2023 17:56:38 AEDT ]]> An enriched environment increases activity in stroke patients undergoing rehabilitation in a mixed rehabilitation unit: a pilot non-randomized controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14102 Sat 24 Mar 2018 08:24:01 AEDT ]]> Exploring the efficacy of constraint in animal models of stroke: meta-analysis and systematic review of the current evidence https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16723 Sat 24 Mar 2018 08:05:31 AEDT ]]> Addition of botulinum toxin type A to casting may improve wrist extension in people with chronic stroke and spasticity: a pilot double-blind randomized trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32790 Mon 23 Sep 2019 10:06:26 AEST ]]> Altering the rehabilitation environment to improve stroke survivor activity: A Phase II trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49585 Mon 22 May 2023 12:22:22 AEST ]]> Physical, cognitive and social activity levels of stroke patients undergoing rehabilitation within a mixed rehabilitation unit https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18704 Mon 20 Jul 2015 17:48:19 AEST ]]> Long-term effect of additional rehabilitation following botulinum toxin-A on upper limb activity in chronic stroke: the InTENSE randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51414 Mon 04 Sep 2023 14:52:01 AEST ]]>